The increased incidence of sepsis and fatal infections in patients treated with canakinumab may be partly explained by the fact that the development of sepsis is associated with increased levels of many pro-inflammatory cytokines, including i.a. IL-7, IL-8, IL-10, IL-13, IFN-γ, MCP-1, and TNF-α [96]. The gene discussed is IL10; the disease is Sepsis.